September 1, 2015
Gilead Sciences K.K.’s hepatitis C drug Harvoni (ledipasvir + sofosbuvir) made a much-anticipated debut on the Japanese market on September 1 after its NHI price listing a day before. The drug is the first once-daily 12-week single-tablet regimen to treat...read more